Hosted on MSN1mon
ODAC to Discuss Exelixis' Application for Cabometyx Label ExpansionExelixis also intends to submit an sNDA with the FDA later this year for cabozantinib, in combination with Tecentriq (atezolizumab ... A potential label expansion should boost sales further.
On Thursday, Tempest Therapeutics Inc. (NASDAQ:TPST) announced feedback from its end-of-Phase 2 meeting with the FDA for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback